InteliSwabᆴ COVID-19 rapid tests receive U.S. FDA authorization for pediatric use
On Jan. 31, 2022, OraSure Technologies announced that its InteliSwabᆴ COVID-19 rapid tests had been authorized by the U.S. Food and Drug Administration (FDA) for use in children ages 2 to 14. InteliSwabᆴ was previously authorized for use in adults and in children 15 to 17 when administered by an adult.
Tags:
Source: OraSure Technologies
Credit: